GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck &
Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial.
GSK says its PD-1 inhibitor Jemperli compared favourably with Merck & Co’s Keytruda in a head-to-head trial in previously-untreated non-small cell lung cancer (NSCLC), with numerically
